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Abstract 
Ulipristal acetate (UPA) is a selective progesterone receptor modulator (PRM), which is used as 
an emergency contraceptive in women. Recent studies demonstrated the efficacy of a UPA 
contraceptive vaginal ring (UPA-CVR) as a blocker of ovulation. However the endometrium of 
women exposed to UPA over a six-month period display glandular changes, termed PRM-
associated endometrial changes (PAECs). We, therefore, investigated whether UPA-induced 
PAECs are associated with altered expression of the transcription factor HAND2 whose down 
regulation is observed in endometrial epithelial hyperplasia and cancer. Our results showed that 
while exposure to mifepristone, a well-known PRM, leads to suppression of endometrial 
HAND2 expression, long-term exposure to UPA-CVR did not cause down regulation of this 
marker. Further studies, using human primary endometrial stromal cells, confirmed that whereas 
mifepristone-mediated suppression of HAND2 elevated the levels of its downstream target 
fibroblast growth factor 18, UPA did not significantly alter the expression of this growth factor. 
A rationale for the differential regulation of HAND2 by these PRMs was provided by our 
observation that mifepristone-bound progesterone receptors turn over at a faster rate than those 
bound to UPA. Collectively, these results support the selective effects of different PRMs and 
indicate that chronic exposure to UPA does not alter the HAND2 pathway whose dysregulation is 
linked to complex atypical endometrial hyperplasia and cancer. The results from this study 
involving a limited number of clinical samples should pave the way for a larger study to 
determine the safety of UPA for long-term use. 
Key words: Ulipristal acetate; Mifepristone; Contraception; Endometrium; HAND2 
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Introduction 
It is estimated that 225 million women worldwide lack access to effective and acceptable 
contraceptive methods. Therefore, the development of novel clinically safe and effective 
methods of fertility control remains a necessity. The steroid hormone progesterone (P) acting 
through its nuclear receptor critically controls the ovulatory process as well as endometrial 
function in the human. Progesterone receptor modulators (PRM) are synthetic compounds that 
interact with the progesterone receptor (PR) to suppress ovulation and/or induce endometrial 
atrophy, resulting in amenorrhea, a condition that is perceived favorably in many cultures around 
the world 
1
. Therefore, the development and use of PRMs as contraceptives is of particular
interest. 
Ulipristal acetate (UPA), also referred to as VA/CDB-2914, is a new and promising PRM 
2-6
.
UPA has been approved as an emergency contraceptive 
7, 8
 in the United States and abroad and
as a treatment for heavy menstrual bleeding due to uterine fibroids 
9, 10
 in Canada and Europe.
Successful use of this PRM as an emergency contraceptive has raised the possibility that a 
simplified continuous delivery of UPA could improve long-term contraceptive safety and 
efficacy and compliance. With this goal in mind, a UPA contraceptive vaginal ring (UPA-CVR) 
was designed for long-term contraceptive use by the Population Council, New York. In a study 
conducted by the Council, healthy women with normal baseline ovulation were randomized to 
receive UPA-CVR for two consecutive 12-week treatment periods, followed by a recovery cycle 
11
. The results from these studies indicated that the UPA-CVR has the potential to become an 
effective long-acting, user-controlled contraceptive. However, endometrial biopsies taken at the 
end of the treatment period displayed histological glandular changes, described as PRM-
associated endometrial changes (PAECs) 
11
. While these endometrial changes are considered to
be benign due to the lack of cytological atypia
12
 an in-depth study is needed to confirm the
absence of any endometrial abnormality, including hyperplasia, following chronic PRM use. 
The endometrium, the innermost layer of the uterus, undergoes proliferation and differentiation 
in a cyclical manner in response to the steroid hormones, 17β-estradiol (E) and P acting via their 
cognate receptors 
13-15
. While E acting via ERα functions as a mitogen and promotes the growth
and proliferation of the endometrial epithelium in a cyclical fashion during the reproductive 
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cycle, P acting via PR inhibits E-induced epithelial proliferation and causes differentiation. 
Uncontrolled proliferation of the endometrial epithelium results in alterations of glandular 
architecture (shape and size) and an increase in endometrial gland-to-stroma ratio, leading to 
endometrial hyperplasia 
15-17
. The majority of cases of endometrial hyperplasia are associated
with compromised P signaling that fails to oppose E signaling 
17-19
.
We have previously shown that the transcription factor HAND2 (Heart- and neural crest 
derivatives-expressed protein 2), which is regulated by the PR present in the endometrial stroma, 
is a key mediator of the well-known anti-proliferative effect of P on the endometrial epithelium 
20
. HAND2 suppresses the production of several stromal fibroblast growth factors (FGFs), which 
act in a paracrine manner via the FGF receptors to promote epithelial proliferation. Therefore, in 
the absence of HAND2, the endometrial epithelium undergoes unbridled FGF-induced 
proliferation that leads to complex atypical hyperplasia. It is of interest to note that the HAND2 
gene locus is prone to epigenetic alterations. Our recent studies revealed that the HAND2 gene is 
a hypermethylated and silenced in endometrial hyperplasia and cancer 
21
. When compared to
other frequent DNA-based alterations in endometrial cancers, such as p53, PTEN, and PIK3CA 
mutations, HAND2 hypermethylation was found to be the most common 
21
. Since the down
regulation of HAND2 expression is linked to endometrial hyperplasia and cancer, we examined 
the expression of this factor in endometrial biopsies of women exposed to UPA-CVR for 24 
weeks. We also compared the endometrial effects of UPA with those of mifepristone, a well-
known PRM. 
Materials and Methods 
Endometrial biopsies 
Endometrial biopsy samples were obtained using either a Pipelle (Cooper Surgical, Trumbull, 
CT, USA) (DR, Chile) or an Explora (Cooper Surgical) (Oregon) device. A portion of wach 
sample was placed for use in 10% neutral buffered formaldehyde for histology and 
immunohistochemistry studies. 
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In vitro decidualization of human endometrial stromal cells (HESC) 
Our studies involving primary HESC cultures follow the regulations stated for the protection of 
human subjects participating in clinical research and are approved by the institutional review 
boards of Emory University, Wake Forest University (Winston-Salem, North Carolina), and the 
University of Illinois at Urbana-Champaign (UIUC). Endometrial samples from the early 
proliferative stage of the menstrual cycle were obtained by Pipelle biopsy at Emory University 
and Wake Forest Medical Centers from fertile, regularly cycling volunteers with no sign of 
uterine abnormality, providing written informed consent as described previously 
21, 22
.
Cells were cultured in DMEM/F-12 medium (Invitrogen) supplemented with 5% (vol/vol) fetal 
bovine serum (Hyclone), 50 µg/mL penicillin, and 50 µg/mL streptomycin (Invitrogen). For in 
vitro differentiation, the cells were treated with differentiation cocktail composed of 10 nM E 
(Sigma), 1 µM progesterone (Sigma), 0.5 mM 8-bromoadenosine-cAMP (Sigma), 10 µM UPA 
or mifepristone in DMEM/F-12 medium (Invitrogen) supplemented with 2% (vol/vol) charcoal 
dextran-stripped fetal bovine serum for 0-6 days. At the end of the culture (2 or 6 days), the cells 
were detached from the plates, counted, and stored at -80°C for RNA extraction. Additionally 
some cells were fixed for immunocytochemical (ICC) analysis. In some experiments, the cells 
were treated with differentiation cocktail composed of 10 nM E, 1 µM progesterone, 0.5 mM 8-
bromoadenosine-cAMP, 5 µM UPA or mifepristone in DMEM/F-12 medium supplemented with 
2% (vol/vol) charcoal dextran-stripped fetal bovine serum for 0-6 days. Cultures were terminated 
at days 2 to 6 for RNA extraction. 
Chemicals, reagents, and antibodies 
Progesterone (P), 17β-estradiol (E), naphthol AS-MX phosphate, Fast Blue RR (4-
benzoylamino- 2,5-dimethoxyaniline diazonium), collagenase, pancreatin, dimethyl sulfoxide 
(DMSO), 8-bromoadenosine 3', 5'-cyclic monophosphate salt (cAMP), and Trypan blue were 
purchased from Sigma. Hanks Balanced Salt Solution (HBSS), dispase, Dulbecco’s modified 
Eagle medium-F12 medium HEPES, no phenol red (DMEM/F12), Penicillin-Streptomycin, and 
Fungizone, were purchased from Life Technologies. Fetal bovine serum (FBS) was purchased 
from Fisher Scientific. Fluoromount-G with DAPI was purchased from eBiosciences. 
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Endometrial sections or endometrial stromal cells were incubated with one or more of the 
following primary antibodies: heart- and neural crest derivatives-expressed transcript 2 
(HAND2, 1:250, Santa Cruz Biotechnology antibody SC-9409), FGF18 (1:100, Santa Cruz 
Biotechnology antibody SC-393471), PR (1:100, DAKO-A0098), and PRB
22
 (1:300, Cell
signaling CST-31575). The fluorescent-tagged secondary antibodies and normal donkey serum 
were purchased from Jackson ImmunoResearch. The following secondary antibodies were used: 
rhodamine or Cy3 donkey anti-rabbit, 488 donkey anti-rabbit, 488 donkey anti-mouse, 488 
donkey anti-goat, and Cy3 donkey anti-rat. 
Immunohistochemistry (IHC) and immunocytochemistry (ICC) 
Paraffin-embedded endometrial biopsy sections were subjected to IHC as described previously. 
Tissue sections were deparaffinized in xylene, rehydrated through a graded series of ethanol, and 
washed in tap water. For most of the immunostaining, antigen retrieval was performed in a 
pressure cooker in 10 mM sodium citrate buffer (pH 6.0) for 20 min and then the slides were 
cooled to room temperature. The sections were washed between steps (three times for 5 min 
each) using 1x phosphate-buffered saline solution containing 0.05% Tween 20 (PBS-T). 
Nonspecific binding was inhibited by incubating the sections with 10% normal serum for 1 h at 
room temperature. After the serum block, sections were incubated overnight at 4°C with the 
diluted antibody solution in PBS-T containing 1% normal serum. 
Labeling was visualized by incubation with a fluorescent-tagged secondary antibody for 1 h at 
room temperature. All incubations were done using a humidified chamber protected from light. 
Slides were mounted using a mounting solution containing DAPI. Pictures were taken using the 
Olympus BX51 microscope equipped for fluorescent imaging and connected to a Jenoptik 
ProgRes C14 digital camera with c-mount interface containing a 1.4 Megapixel CCD sensor. 
Fluorescent images were processed and merged using Adobe Photoshop Extended CS6 (Adobe 
Systems). HSCOREs were determined as described previously 
23
.
For ICC analysis of HESC, cells were fixed in 10% NBF for 10 min, and then washed with PBS. 
Cells were then permeabilized using PBS containing 0.1% Triton X for 10 min at room 
temperature. Nonspecific binding was inhibited by incubating the sections with 10% normal 
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serum for 1 h at room temperature. After the serum block, the cells were incubated overnight at 
4°C with the diluted antibody solution in PBS containing 1% normal serum. Labeling was 
visualized by incubation with a fluorescent-tagged secondary antibody for 1 h at room 
temperature. One drop of mounting solution containing DAPI was added to each well to stain the 
nucleus. Pictures were taken using the Olympus Ix70 inverted microscope adapted to a 
Diagnostic Instrument digital camera containing a 2.0 Megapixel CCD sensor. Fluorescent 
images were merged and processed using Adobe Photoshop Extended CS6. 
Quantitative real time PCR analysis (qPCR) 
Total RNA was isolated from endometrial cells using a standard TRIzol-based protocol. The 
RNA concentration of each sample was determined at 260 nm using a Nanodrop ND1000 UV-
Vis spectrophotometer (Nanodrop Technologies). RNA samples were reverse transcribed using 
the High Capacity cDNA Reverse Transcription kit (Applied Biosystems) according to the 
manufacturer's instructions. Real time quantitative PCR (qPCR) reactions were carried out using 
SYBR-green master mix (Applied Biosystems) in a 7500 Applied Biosystems Real-time PCR 
machine (Applied Biosystems). For each sample, the mean threshold cycle (Ct) was calculated 
from Ct values obtained from three replicates. The normalized ∆Ct in each sample was 
calculated as mean Ct of target gene subtracted by the mean Ct of the reference gene. The fold 
change of gene expression in each sample relative to a control was generated using the 2−∆∆Ct 
mathematical model for relative quantification of quantitative PCR. The mean fold induction and 
SEM were calculated from at least three or more independent experiments. The housekeeping 
gene RPLP0 (36B4), which encodes a ribosomal protein, was used as a reference gene. 
Statistical analyses 
Experimental data for studies related to UPA-CVR were collected from 12 independent subjects. 
For each subject, 4 endometrial biopsy samples were obtained. Biopsy 1 was an endometrial 
specimen obtained before administration of UPA-CVR, biopsies 2 and 3 were endometrial 
specimens obtained after each 12-week period in which UPA-CVR released UPA daily, and 
biopsy 4 was obtained following a 4-week post-treatment recovery period. Results from 
mifepristone studies were obtained from 6 independent clinical samples. Data related to primary 
HESCs were collected from 3 independent clinical samples, which were subjected to the same 
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experimental conditions. All numerical data are expressed as mean ± SEM. When experimental 
samples were compared with control samples, statistical significance between the control and 
experimental sample was determined using the Student t test. A P value of ≤.05 was considered 
to be significant. 
Results 
Expression of HAND2 is unaltered in human endometrial biopsies exposed to UPA-CVR 
Human endometrial biopsies were obtained from three different clinics located in the United 
States, Dominican Republic, and Chile. We have analyzed a total of 12 independent subjects. 
For each subject, 4 endometrial biopsy samples (biopsies 1-4) were obtained. Biopsy 1 is an 
endometrial specimen obtained before administration of UPA-CVR during the luteal phase based 
on urine LH determinations. Biopsies 2 and 3 are endometrial specimens obtained after each 12-
week period in which UPA-CVR released 1.5 mg or 2.5mg UPA daily. Biopsy 4 was obtained 
following a 4-week post-treatment recovery period in the luteal phase, determined as above. 
Figure 1 shows representative endometrial samples at baseline, before administration of UPA-
CVR (panel A), after exposure to UPA-CVR (panel B), and in the recovery phase (panel C). 
Baseline samples show normal mid-secretory phase endometrium. Upon exposure to UPA-CVR, 
the glands show variable cystic dilatation, mildly disordered architecture, non-physiological 
secretory appearances, and coexistent mitoses and apoptotic bodies. The stroma is compact, non-
decidualized and contains occasional thick-walled vessels. These features are characteristic of 
PRM-associated endometrial changes or PAECs. In the recovery phase, the endometrium 
exhibits normal early secretory phase appearances. 
To examine the molecular changes in the endometrium following prolonged exposure to UPA-
CVR, we investigated the expression of HAND2 in the biopsy specimens. An intense nuclear 
staining specific to HAND2 was observed in the endometrial stromal cells of pre-treatment 
biopsy-1 specimen (Figure 2). This expression of stromal HAND2 remained unaltered in the 
biopsies exposed to UPA (biopsy-2, and -3, Figs. 2B and C) and in the post-treatment biopsy 
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specimen (biopsy-4, Fig. 2D). To more accurately quantify the immunohistochemical findings, 
HSCOREs were analyzed. HSCORES of endometrial HAND2 immunostaining revealed no 
significant changes across the treatment period (Figure 3). These results indicate that a CVR 
releasing 1.5 or 2.5mg/day of UPA for 24 weeks does not affect HAND2 expression. 
Expression of HAND2 is reduced in human endometrial biopsies exposed to mifepristone 
We also analyzed the expression of HAND2 in endometrial biopsies collected from women 
exposed to mifepristone, a well-known PRM. In this study, 50 mg of oral mifepristone was 
administered every other day for 12 weeks. Endometrial biopsies were taken in the secretory 
phase of the last week of mifepristone treatment. Luteal phase biopsies from unexposed women 
demonstrated robust expression of HAND2 in the nuclei of stromal cells, as expected. In 
contrast, endometrial biopsies of women treated with mifepristone showed a significant decline 
in the expression of HAND2 (Figure 4). Quantification of HAND2 immuno-positive cells in the 
stroma revealed greater than 80% reduction in HAND2 expression in mifepristone-exposed 
biopsies when compared to unexposed controls. Collectively, these results suggest that UPA-
CVR and mifepristone have differential effects on endometrial HAND2 expression. It is possible 
that the differences are due to the pharmacology of the PRM compounds, their doses, duration or 
route of administration. 
UPA and mifepristone differentially regulate HAND2 and FGF18 expression in cultured 
human endometrial stromal cells 
To directly examine the pharmacological effects of UPA and mifepristone on HAND2 
expression in the endometrial stroma under identical study conditions, we utilized a well-
established human endometrial stromal cell culture system. In this system, undifferentiated 
stromal cells isolated from human endometrial biopsies (HESC) obtained from normal women in 
the proliferative stage of the menstrual cycle were placed in culture and subjected to 
decidualization in response to a hormonal mixture containing 10 nM E, 1 µM P, and 0.5 mM 8-
bromo-cAMP 
24, 25
. Under the treatment conditions, cells were treated with the hormonal mixture
with or without 10 µM UPA or mifepristone. HESCs were cultured in the presence of hormones 
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with or without PRMs for up to six days. HAND2 mRNA expression was reduced when 
endometrial stromal cells were exposed to UPA or mifepristone for two days, compared to cells 
not treated with PRMs (Figure 5). While UPA exposure reduced HAND2 expression by 20%, 
treatment with mifepristone resulted in almost 40% reduction in HAND2 expression (P<0.05). 
Further, the inhibitory effect of mifepristone on HAND2 expression increased in severity with 
longer duration of treatment. Stromal cells exposed to mifepristone for six days displayed more 
than 80% reduction in HAND2 expression when compared to untreated control cells. In contrast, 
treatment with UPA for six days had milder effects, resulting in a 30% reduction in HAND2 
expression (P<0.05). Consistent with the RNA profile, immunocytochemical (ICC) analysis 
revealed similar reductions in HAND2 in the UPA (Figure 6, panel B)- and mifepristone (Figure 
6, panel C) -exposed endometrial stromal cells compared to UPA- or vehicle-treated stromal 
cells (Figure 6, panel A). 
To further investigate the differential effects of UPA and mifepristone on HAND2 expression, 
we reduced the levels of PRMs from 10-fold to 5-fold molar excess of P. Human endometrial 
stromal cells were cultured in the presence of hormones with or without 5 µM UPA or 
mifepristone for up to six days. HAND2 mRNA expression was monitored on day 2, day 3, day 
4, day 5, and day 6 after initiation of the culture. As shown in Figure 7, treatment of HESC with 
5 µM UPA did not affect the expression of HAND2 on days 2 to 6 upon initiation of the culture. 
By contrast, administration of 5 µM mifepristone led to a significant down regulation of HAND2 
expression in HESCs. The decline in HAND2 expression was evident on day 2 and continued up 
to day 6 of culture. 
Our previous studies have shown that Hand2 expression in the stroma suppresses the production 
of fibroblast growth factors (FGFs) and inhibits cell proliferation 
20
. In the absence of Hand2,
continued induction of FGFs in the stroma activates FGF receptor (FGFR) signaling in the 
epithelium to promote cell proliferation 
20
. Consistent with this observation, a recent study 
reported a decrease in HAND2 expression and marked increase in the levels of FGF18 in human 
endometrial adenocarcinoma 
26
. Mifepristone-treated endometrial stromal cells demonstrated a
marked increase in the levels of FGF18 mRNA (Figure 8, upper panel) and protein (Figure 8, 
lower panel) compared to vehicle-treated controls. In contrast, endometrial stromal cells exposed 
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to UPA did not exhibit alterations in FGF18 expression (Figure 8). Collectively, these results 
support our in vivo findings and indicate that endometrial stromal cells cultured with 
mifepristone or UPA under identical in vitro conditions exhibit differential effects on HAND2 
and FGF18 expression. 
Mifepristone and UPA differentially affect PR stability in human endometrial stromal cells 
Both UPA and mifepristone are known to regulate the function of a tissue by modulating the 
activity of PR, so it is interesting that endometrial stromal cells display differential gene 
expression when exposed to the same concentrations of these two PRMs. We considered the 
possibility that the stability of endometrial PR might be regulated differentially by mifepristone 
and UPA. To investigate this possibility, we determined the expression of total PR protein in 
progesterone-, UPA-, or mifepristone-treated HESC by ICC. Cells exposed to progesterone or 
UPA for 6 days displayed prominent nuclear PR staining, while those treated with mifepristone 
showed markedly reduced levels of PR (Figure 9). 
Our recent studies revealed that the PR isoform PR-B plays a predominant functional role during 
human endometrial stromal differentiation by controlling the expression of a large number of 
target genes, including HAND2 
21
. We noted distinct expression of PR-B 
22
 in the nuclei of
progesterone- or UPA-treated stromal cells (Figure 10). In contrast, nuclei of stromal cells 
exposed to mifepristone were mostly devoid of PR-B expression. Taken together, these results 
are consistent with our view that UPA and mifepristone differentially affect PR stability in 
human endometrial stromal cells and this is reflected in altered expression of PR target genes, 
such as HAND2, in response to these ligands in the endometrial stroma. 
Discussion 
A critical balance of E and P drives proper endometrial stromal-epithelial crosstalk and 
maintains normal uterine physiology. Disruption of PR function results in unopposed E action, 
causing epithelial hyperplasia and potentially carcinoma 
17-19
. HAND2, a PR-regulated gene in
the stromal cells, mediates the antiproliferative action of P to regulate endometrial epithelial 
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function. Loss of the antiproliferative actions of P in the uterus has been linked to E-dependent 
endometrial cancer 
27
. Indeed, our recent study showed that the HAND2 gene is hypermethylated
in premalignant endometrial lesions compared to normal endometrium and its expression is 
suppressed in endometrial hyperplasia and cancer 
21
. HAND2 has therefore emerged as a key
molecular alteration in endometrial cancer that could potentially be employed as a biomarker for 
early detection of endometrial cancer. 
To determine the clinical utility of UPA as a long-term contraceptive, it is critical to assess 
whether this compound, which effectively blocks PR action and ovulation, also alters the critical 
balance of E and P in the endometrium. Evaluation of endometrial histology following chronic 
UPA treatment revealed the presence glandular changes, known as PAECs, which did not show 
any cytological atypia, a characteristic feature of hyperplasia and cancer. However, routine 
histological examination of the endometrium may not provide molecular information related to a 
subtle imbalance of E- and P-dependent signaling that may arise due to PRM exposure. In this 
study, we show that the expression of HAND2, which critically regulates the balance of P- and 
E- dependent signaling in the endometrium, is unaffected in women exposed to UPA-CVR 
continuously for 24 weeks. Since downregulation of endometrial HAND2 has been linked to 
complex atypical hyperplasia and cancer, unaltered expression of this factor gives us confidence 
that exposure to the studied dose of UPA by the vaginal route of administration does not disrupt 
the critical balance of E- and P- dependent signaling necessary for normal endometrial 
physiology. 
In contrast, we found that endometrial biopsies from women treated with mifepristone for 12 
weeks displayed a dramatic downregulation of HAND2. Differential effects of UPA and 
mifepristone on HAND2 expression were confirmed in endometrial stromal cells cultured under 
identical conditions, suggesting distinct mechanisms underlie the actions of these PRMs. 
Analysis of PR in endometrial stromal cells following in vitro exposure to PRMs demonstrated 
that mifepristone down regulates the PR levels, whereas equivalent molar concentrations of UPA 
did not have these effects. This suppression of cellular PR levels by mifepristone is consistent 
with previous reports that addition of mifepristone to a progestogen-only regimen of 
contraception leads to downregulation of PR-B 
28
. Additionally, recent studies have 
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demonstrated that administration of mifepristone to an endometrial co-culture system causes 
suppression of PR expression compared to vehicle-treated controls 
29
. While the mechanism by
which mifepristone causes PR turnover remains unclear, we believe that this downregulation of 
PR is in part responsible for the dramatic suppression of HAND2 expression observed in 
response to mifepristone compared to UPA. 
We have previously shown that HAND2 mediates the antiproliferative effects of P by 
suppressing the production of the FGF growth factors that mediate the growth-inducing effects 
of E on the endometrial epithelium. In the E-dominant proliferative endometrium, FGFs secreted 
from the stroma act on the FGFR(s) in the epithelium to promote proliferation 
20
. Following
ovulation and in response to P production and signaling, HAND2 is induced in stromal cells, 
causing inhibition of FGF synthesis and attenuation of epithelial proliferation. Disruption of PR 
function in the endometrium therefore runs the risk of increasing FGF signaling, leading to 
inappropriate uterine epithelial growth, hyperplasia and cancer. Similar findings were noted in 
the epithelial glands of rhesus macaques treated with mifepristone 
30
. Indeed, a recent study has
shown downregulation of HAND2 and upregulation of FGF18 in human endometrial 
adenocarcinoma 
26
. We demonstrate that administration of mifepristone to cultured endometrial
stromal cells caused inhibition of HAND2 expression and a concomitant enhancement of FGF18 
expression. However, treatment of endometrial stromal cells with UPA did not significantly 
affect the expression of either HAND2 or FGF18, further confirming that UPA does not 
significantly alter the P-dependent antiproliferative pathways in the endometrium. 
In summary, this study shows that UPA and mifepristone exhibit differential effects on 
endometrial gene expression in vivo and in vitro, apparently due to differences in stability of PRs 
in response to these PRMs. It also confirms that chronic exposure to UPA-CVR over a 24-week 
period does not lead to adverse effects, such as suppression of the expression of HAND2, which 
is reported to occur in endometrial hyperplasia and cancer. The results from this study involving 
a limited number of clinical samples should pave the way for a larger study to determine the 
safety of UPA for long-term use. 
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Figure legends 
Fig. 1: Endometria of women exposed to UPA-CVR display PRM-associated endometrial 
changes (PAECs). Haematoxylin & eosin staining of endometrial sections obtained from normal 
mid-secretory phase endometrium (panel A), UPA-CVR releasing 2.5mg UPA daily for two 
consecutive 12-week treatment periods (panel B), and post-treatment recovery period in the 
luteal phase (panel C). Note cystic dilatation, mildly disordered architecture, and non-
physiological secretory appearances in the endometria of women with UPA-CVR. These 
endometrial samples are part of the large clinical trial. Representative images are shown. 
Fig. 2: Expression of HAND2 in human endometrial biopsies exposed to UPA-CVR for 24 
weeks. Immunohsitochemical localization of HAND2 in endometrial sections before and after 
exposure to UPA-CVR. A total of 12 independent subjects were analyzed and for each subject, 4 
endometrial biopsy samples were obtained (N=48). Panel A represents endometrial specimen 
obtained during the luteal phase before administration of UPA-CVR. Panels B and C indicate 
endometrial specimens obtained after each 12-week period with UPA-CVR releasing 1.5mg or 
2.5mg UPA daily. Panel D represents endometrial specimen collected during the luteal phase 
following a post-treatment recovery period. Panel E shows endometrial sections from a biopsy 
sample after a 12-week exposure to UPA-CVR and subjected to IHC protocol omitting the 
primary antibody. Red staining indicates positive staining for HAND2 in endometrial sections. 
Representative images are shown. S and E indicate stroma and epithelium respectively. 
Fig. 3: HAND2 expression is unaltered in human endometrial biopsies exposed to UPA-
CVR. The percentages of the immunostaining positive cells for HAND2 were analyzed by 
ImageJ software. The values represent mean ± SEM of twelve independent samples (N=5 for 
UPA-CVR releasing 1.5 mg and N=7 for UPA-CVR releasing 2.5mg UPA daily) with a total of 
N=48 clinical samples. No obvious dose-response effects were noted between the two doses. 
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Fig. 4: Expression of HAND2 is reduced in human endometrial biopsies exposed to 
mifepristone. Upper: Immunohistochemical analysis of HAND2 in human endometrium before 
(panel A) and after administration of 50 mg of oral mifepristone every other day for 12 weeks of 
the menstrual cycle (panel B). Representative images are shown. Lower: HSCORES of 
HAND2-positive cells in the endometrium revealed a significant reduction in HAND2 
expression in mifepristone-exposed biopsies when compared to unexposed controls (N=6). B 
indicates baseline (0 wks) and after 12 weeks (12 wks) indicates end of treatment, respectively, 
and shows a significant decrease (P<0.02).   
Fig. 5: UPA and mifepristone differentially regulate HAND2 mRNA expression in human 
endometrial stromal cells. Primary cultures of human stromal cells were grown in Dulbecco's 
modified Eagle's medium/F-12 medium containing 5% charcoal-stripped fetal bovine serum. The 
cells were treated with a hormone mixture containing 10 nM E, 1 µM P, 0.5 mM 8-bromo-
cAMP, and 10 µM UPA, mifepristone or vehicle for 6 days. Cells were harvested 2 days (left 
panel) or 6 days (right panel) after addition of hormone mixture. Total RNA was isolated and 
subjected to qPCR using primers for HAND2. The level of Rplp0 was used as an internal control 
to normalize gene expression. The values are presented as the mean fold induction ± SEM, 
P<0.05. 
Fig. 6: UPA and mifepristone differentially regulate HAND2 protein expression in human 
endometrial stromal cells. Immunocytochemical analysis of HAND2 in stromal cells during in 
vitro decidualization. Panels represent primary cultures of human endometrial stromal cells 
cultured in the absence of UPA or mifepristone (A), in the presence of UPA (B), in the presence 
of mifepristone (C) for 6 days. Representative images from three independent experiments are 
shown. 
Fig. 7: UPA and mifepristone differentially regulate HAND2 mRNA expression in human 
endometrial stromal cells. Primary cultures of human stromal cells were treated with a hormone 
mixture containing 10 nM E, 1 µM P, 0.5 mM 8-bromo-cAMP, and 5 µM UPA, mifepristone or 
vehicle for 6 days. Cells were harvested 2, 3, 4, 5, and 6 days after addition of hormone mixture. 
Total RNA was isolated and subjected to qPCR using primers for HAND2. The level of Rplp0 
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was used as an internal control to normalize gene expression. The values are presented as the 
mean fold induction ± SEM, *P<0.05, **P<0.01. 
Fig. 8: Downregulation of FGF18 expression in response to mifepristone in human 
endometrial stromal cells. Human endometrial stromal cells were subjected to differentiation in 
response to 0.5 mM 8-bromo-cAMP, 1 µM P, 10 nM E, and 10 µM UPA or mifepristone for 6 
days. Upper. Total RNA was isolated and subjected to qPCR using primer for FGF18. Y-axis 
indicates fold induction. The level of Rplp0 was used as an internal control to normalize gene 
expression. The data are represented as the mean fold induction ± SEM from three separate 
samples. Lower. Immunocytochemical analysis of FGF18 expression in endometrial stromal in 
the absence of UPA or mifepristone (left panel), in the presence of UPA (middle panel) and in 
the presence of mifepristone (right panel). Representative images are shown. 
Fig. 9: PR stability in response to UPA or mifepristone in human endometrial stromal cells. 
Primary cultures of human stromal cells were treated with a hormone mixture containing 10 nM 
E, 1 µM P, 0.5 mM 8-bromo-cAMP, and 10 µM UPA, mifepristone or vehicle for 6 days. 
Immunocytochemical analysis of PR in endometrial stromal in the absence of UPA or 
mifepristone (left panel), in the presence of UPA (middle panel) and in the presence of 
mifepristone (right panel) are shown. Representative images are shown. 
Fig. 10: PR-B stability in response to UPA or mifepristone in human endometrial stromal 
cells. Primary cultures of human stromal cells were treated with a hormone mixture containing 
10 nM E, 1 µM P, 0.5 mM 8-bromo-cAMP, and 10 µM UPA, mifepristone or vehicle for 6 days. 
PR-B expression in endometrial stromal in the absence of UPA or mifepristone (left panel), in 
the presence of UPA (middle panel) and in the presence of mifepristone (right panel) are shown. 
Representative images are shown. 
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